Millions of people suffer from sleep apnea every single night
We will not rest until they sleep peacefully
Restera is a clinical-stage medical technology company developing a first-of-its-kind treatment for sleep apnea.
Restera has united a world-class team of clinicians, engineers, investors, and leading research institutions with a shared mission: to deliver a transformative treatment for Obstructive Sleep Apnea (OSA).
Restera’s Board of Directors brings deep operational, clinical, and financial expertise across the medical technology and life sciences sectors. The company’s Scientific Advisory Board includes leading experts from renowned institutions such as the University of Pennsylvania, Vanderbilt University, Stanford University, Flinders University, and Monash University.
Sleep Apnea is a Significant Global Problem
One Billion
Sleep apnea sufferers worldwide
Current solutions are not working. Continuous positive airway pressure (CPAP) therapy accounts for 85% of diagnosed sleep apnea patients, yet nearly half don’t comply with the therapy. The devices are cumbersome, loud, uncomfortable and overall intrusive.
Eighty Percent
Remain undiagnosed
When untreated, sleep apnea is linked to serious and costly conditions, including drug-resistant hypertension, obesity, congestive heart failure, type-2 diabetes, atrial fibrillation and more.
$150 Billion
Economic impact of sleep apnea in the US
Untreated sleep apnea costs the U.S. approximately $150 billion annually, due to the healthcare costs associated with these untreated conditions, as well as loss of productivity, workplace accidents and motor vehicle accidents.
Restera is Working on a Transformative Solution
A miniature device, placed through a needle in minutes, opens the airway for measurably improved breathing.
Our therapy leverages safe, well-established neurostimulation technology in a miniature implant. The device is designed to be injected in a simple outpatient procedure, leaving no visible scars and enabling patients to return to daily life with minimal disruption.
During sleep, the system improves breathing by providing stimulation to open the airway.
“a level of flow restoration not yet seen with any other stimulation”
Our mission to improve sleep for millions with OSA is focused on three key areas of innovation:
Better Neural Targets: Restera has pioneered novel neural targets including a new area of the Hypoglossal nerve (HGN) as well as the Ansa Cervicalis (AC) nerve. Early results indicate each of these targets provide significant therapeutic benefit.
Skip The Scalpel: Restera is combining proven ultrasound guidance together with injection through a needle to minimize or eliminate the need for any incision.
Precision Placement: Our patented, innovative tools and methods are designed to allow quick, accurate placement of the device in minutes in an outpatient setting.
6
Clinical Studies
68
Subjects
54
Patents
15
Peer Review Publications
We are already demonstrating success in the clinic, with more clinical work underway.
Learn more about our clinical strategy here:
Clinical Overview
